Debut Plus

1,174

-31.34 -2.60%

18 Jul 2026

NSE Listed

Entero Healthcare Solu Limited (ENTERO)

Volume: 95,083Avg Vol 1W: 74,759.4Avg Vol 1M: 83,886.952W Range:9441,390
Market Cap₹4,854 Cr
Current Price₹1,174
Previous Close₹1,205.34
High / Low (52w)₹1,390 / ₹944
Volume95,083
Avg Vol (1W)74,759.4
Avg Vol (1M)83,886.9
Stock P/E52.16
Book Value₹395.31
Dividend Yield
ROE6.3%
ROA
Revenue (TTM)₹5,135 Cr
Revenue Growth
Profit Margin
Total Debt₹0 Cr
Shares Outstanding
Face Value₹10
EPS (TTM)₹24.69
P/B2.88
Debt / Equity0.22
50 DMA₹1,184.35
200 DMA₹1,134.97
Day change-2.60%
Price Chart
1,174 1.15% · 1Y
135494916.2L
2025-07-17
2026-07-16

20-day avg volume: 84K shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 24% YoY.
  • Stock trades at a high P/E of 52.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹1,097 Cr₹1,301 Cr₹1,359 Cr₹1,339 Cr₹1,404 Cr₹1,571 Cr₹1,707 Cr₹1,910 Cr
EBITDA₹37 Cr₹46 Cr₹49 Cr₹48 Cr₹47 Cr₹57 Cr₹63 Cr₹75 Cr
Net Profit₹20 Cr₹24 Cr₹25 Cr₹26 Cr₹28 Cr₹32 Cr₹28 Cr₹28 Cr
EPS
Profit & Loss (Annual)
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹1,354 Cr₹1,784 Cr₹2,527 Cr₹3,306 Cr₹3,937 Cr₹5,135 Cr
EBITDA₹17 Cr₹9 Cr₹9 Cr₹45 Cr₹101 Cr₹180 Cr
Net Profit₹1 Cr₹-16 Cr₹-30 Cr₹-12 Cr₹39 Cr₹95 Cr
EPS0.02-0.3-191.9-0.1810.8121.76
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹749 Cr₹836 Cr₹1,126 Cr₹1,309 Cr₹2,345 Cr₹2,703 Cr
Total Liabilities₹325 Cr₹349 Cr₹563 Cr₹711 Cr₹704 Cr₹932 Cr
Equity₹424 Cr₹487 Cr₹563 Cr₹598 Cr₹1,641 Cr₹1,770 Cr
Total Debt
Cash Flow
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹-32 Cr₹-64 Cr₹-24 Cr₹-33 Cr₹-24 Cr₹-39 Cr
Investing₹-203 Cr₹-31 Cr₹-162 Cr₹-49 Cr₹-705 Cr₹220 Cr
Financing₹217 Cr₹89 Cr₹211 Cr₹73 Cr₹863 Cr₹-74 Cr
Free Cash Flow₹-32 Cr₹-64 Cr₹-24 Cr₹-33 Cr₹-24 Cr₹-39 Cr
Shareholding
Promoter 52.42% Institutions 20.65% Public 26.93%
Efficiency & Working Capital
ROCE9.7%
Interest Coverage4.3
Dividend Payout
Debtor Days59 d
Inventory Days47 d
Payable Days28 d
Cash Conversion Cycle78 d
Working Capital Days107 d
Shareholding Details

As of 2026-03-31

Promoter52.4%
FII4%
DII16.6%
Institutions20.7%
Public26.9%
Promoter Pledge0%
No. of Shareholders39,083
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Feb 2024Feb 2024Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Promoters78.8%52.4%52.4%52.4%52.4%52.4%52.4%52.4%52.4%52.4%52.4%52.4%
FIIs0%22.8%22.8%23.3%23.3%23.8%22.2%19.9%17.2%14.7%5.1%4%
DIIs0%2.2%1.4%2.3%2.1%7.7%8.8%9.6%10.2%9.6%16.4%16.6%
Public21.2%22.6%23.4%22%22.2%16%16.6%18%20.2%23.3%26%26.9%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders511,14,2601,14,26080,86466,40036,76733,17233,15933,33836,33440,33239,083
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Orbimed Asia Iii Mauritius LimitedShareholding of Promoter and Promoter Group38%1.65 Cr
Surbhi Singh(prasid Uno Family Trust)Public Shareholding10.5%45,50,320
Prabhat AgrawalShareholding of Promoter and Promoter Group9.3%40,28,395
Prem SethiShareholding of Promoter and Promoter Group5.2%22,39,842
Icici Prudential Value FundPublic Shareholding4.8%20,97,962
Invesco India Aggressive Hybrid FundPublic Shareholding4.4%18,93,088
Cif Iii Scheme IPublic Shareholding2%8,48,060
Csim India Opportunities Fund 1Public Shareholding1.1%4,85,000
Persistence Capital Fund IPublic Shareholding1%4,36,583
Technomax InfosolutionsShareholding of Promoter and Promoter Group0%0
Uquifa Sciences Mascarene Ltd MauritiusShareholding of Promoter and Promoter Group0%0
Uquifa Sciences Uk LtdShareholding of Promoter and Promoter Group0%0
Uquifa Sciences Slu SpainShareholding of Promoter and Promoter Group0%0
Union Quimico Farmaceutica Sau SpainShareholding of Promoter and Promoter Group0%0
Uquifa Mexico Sa MexicoShareholding of Promoter and Promoter Group0%0
Holliday International LtdShareholding of Promoter and Promoter Group0%0
Soneas Chemicals HungaryShareholding of Promoter and Promoter Group0%0
Uquifa India LimitedShareholding of Promoter and Promoter Group0%0
Orbimed Asia Partners Iii, L.p.Shareholding of Promoter and Promoter Group0%0
Richa AgarwalShareholding of Promoter and Promoter Group0%300
Arti MittalShareholding of Promoter and Promoter Group0%143
Payal AgrawalShareholding of Promoter and Promoter Group0%0
Kunjbehari Lal AgrawalShareholding of Promoter and Promoter Group0%0
Asha AgrawalShareholding of Promoter and Promoter Group0%0
Neha AgrawalShareholding of Promoter and Promoter Group0%0
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Prabhat Agrawal00%2026-03-31
Prem Sethi00%2026-03-31
Richa Agarwal00%2026-03-31
Arti Mittal00%2026-03-31
Payal Agrawal00%2026-03-31
Kunjbehari Lal Agrawal00%2026-03-31
Asha Agrawal00%2026-03-31
Neha Agrawal00%2026-03-31
Jaibhagwan Mittal00%2026-03-31
Komal Gupta00%2026-03-31
Kunal Mittal00%2026-03-31
Vikas Sethi00%2026-03-31
Board of Directors
NameDesignationYear
Sujesh VasudevanChairman & Independent Director2025
Prabhat AgrawalED / MD / CEO / Promoter2025
Prem SethiED / WTD / CFO / Promoter2025
Rajesh Shashikant DalalIndependent Non Exe. Director2025
SANDHYA SHARMAIndependent Non Exe. Director2025
Arun SadhanandhamNon Independent Non Executive Director / Nominee2025
Kevin Rohitbhai DaftaryNon Independent Non Executive Director / Nominee2025
Sumona ChakrabortyNon Independent Non Executive Director / Nominee2025
SANU VISHAL KAPOORVP / Company Secretary / Compliance Officer2025
Segments — Product
SegmentRevenueShare
Trading of Pharmaceutical and Surgi₹0 Cr
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10754344
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20253,219001003,229
20251,26100001,261
20251,70300901,712
Insider / Designated-Person Trades

3 recent disclosure(s)

Jayant PrakashDisposal · 2,179
Jayant PrakashDisposal · 1,350
Abhitsh KumarDisposal · 1,200
Substantial Acquisitions (SAST)

13 disclosure(s)

Market29/12/2025 · 22,77,083
Market29/12/2025 · 21,82,039
Market11/08/2025 · 9,846
Market23/01/2025 · 1,03,982
Market09/01/2025 · 31,596
Release of Shares01/10/2024 ·
Company Information
Incorporated2018
ChairmanSujesh Vasudevan
AuditorMSKA & Associates
Investor Email[email protected]
🌐 www.enterohealthcare.com

📍 Plot # I-35 Bldg-B Ind. Area, Phase-I 13/7 Mathura Road, Faridabad, Haryana, 121003

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search